A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 21 Jul 2020 Results published in the ClinicalTrials.gov Trial Registry
- 21 Jul 2020 Primary endpoint (Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month) has not been met as per results published in the ClinicalTrials.gov Trial Registry
- 05 Jun 2018 Results (n=419) presented at the Digestive Disease Week 2018.